Abdulaziz Alhussan

Dr. Abdulaziz Alhussan

Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia, Canada
orcid
Nuclear Engineer | Physicist | Nanomedicine Scientist

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2023 in Biomaterials Science
Verified
Journal Article
Open access
PDF file
RSRuchi Sharma
Ruchi Sharma
Milena Restan PerezMilena Restan Perez
Milena Restan Perez
Victor Allisson da SilvaVictor Allisson da Silva
Victor Allisson da Silva
JTJess Thomsen
Jess Thomsen
LBLavanya Bhardwaj
Lavanya Bhardwaj
Stephanie WillerthStephanie Willerth
Stephanie Willerth
Cancer is characterized by the uncontrolled division of cells, resulting in the formation of tumors. The tumor microenvironment (TME) consists of a variety of cell types present within a heterogeneous extracellular matrix (ECM). Current 2D culture methods for mimicking this microenvironment remain limited due to spatial constraints. Many different types of 3D cancer models have been developed in recent years using spheroids/organoids, biomaterial scaffolds, and cancer-on-chip systems. However, these models cannot precisely control the organization of multiple cell types inside of complex architectures. Bioprinted cancer models can incorporate both stromal and cancer cells inside of 3D constructs to generate custom models of this complex disease. 3D bioprinting can generate complex, multicellular, and reproducible constructs where the matrix composition and rigidity are tailored locally to the tumor. These capabilities make 3D bioprinting an attractive method for reproducing the tumor TME found in vivo. Recent advancements in biomaterial-based bioinks enable the generation of 3D bioprinted cancer models that accurately mimic the TM. Here we discuss recent examples of such 3D-bioprinted cancer models, including those of the lungs, prostate, skin, brain, and colon. We then highlight the advantages of using 3D bioprinting compared to other in vitro modeling techniques and detail its limitations.

23 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
KBKyle Bromma
Kyle Bromma
Abdulaziz AlhussanAbdulaziz Alhussan
Abdulaziz Alhussan
MPMonica Mesa Perez
Monica Mesa Perez
PHPERRY HOWARD
PERRY HOWARD
WBWayne A Beckham
Wayne A Beckham
DCDevika Chithrani
Devika Chithrani
Radiotherapy and chemotherapy are the gold standard for treating patients with cancer in the clinic but, despite modern advances, are limited by normal tissue toxicity. The use of nanomaterials, such as gold nanoparticles (GNPs), to improve radiosensitivity and act as drug delivery systems can mitigate toxicity while increasing deposited tumor dose. To expedite a quicker clinical translation, three-dimensional (3D) tumor spheroid models that can better approximate the tumor environment compared to a two-dimensional (2D) monolayer model have been used. We tested the uptake of 15 nm GNPs and 50 nm GNPs on a monolayer and on spheroids of two cancer cell lines, CAL-27 and HeLa, to evaluate the differences between a 2D and 3D model in similar conditions. The anticancer drug docetaxel (DTX) which can act as a radiosensitizer, was also utilized, informing future potential of GNP-mediated combined therapeutics. In the 2D monolayer model, the addition of DTX induced a small, non-significant increase of uptake of GNPs of between 13% and 24%, while in the 3D spheroid model, DTX increased uptake by between 47% and 186%, with CAL-27 having a much larger increase relative to HeLa. Further, the depth of penetration of 15 nm GNPs over 50 nm GNPs increased by 33% for CAL-27 spheroids and 17% for HeLa spheroids. These results highlight the necessity to optimize GNP treatment conditions in a more realistic tumor-life environment. A 3D spheroid model can capture important details, such as different packing densities from different cancer cell lines, which are absent from a simple 2D monolayer model.

25 March 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Abdulaziz AlhussanAbdulaziz Alhussan
Abdulaziz Alhussan
EBEce Pinar Demirci Bozdoğan
Ece Pinar Demirci Bozdoğan
DCDevika Chithrani
Devika Chithrani
About half of cancer patients (50%) receive radiotherapy (RT) for the treatment of local tumors. However, one of the main obstacles in RT is the close proximity of adjacent organs at risk, resulting in treatment doses being limited by significant tissue toxicity, hence preventing the necessary dose escalation that would guarantee local control. Effective local cancer therapy is needed to avoid progression of tumors and to decrease the development of systemic metastases which may further increase the possibility of resection. In an effort to do so, radiosensitizing agents are introduced to further increase damage to the tumor while minimizing normal tissue toxicity. Cisplatin and docetaxel (DTX) are currently being used as radiation dose enhancers in RT. Recent research shows the potential of gold nanoparticles (GNPs) as a radiosensitizing agent. GNPs are biocompatible and have been tested in phase I clinical trials. The focus will be on exploring the effects of adding other radiosensitizing agents such as DTX and cisplatin to the GNP-RT platform. Therefore, a combined use of local radiosensitizing agents, such as GNPs, with currently available radiosensitizing drugs could make a significant impact in future RT. The ultimate goal is to develop treatments that have limited or nonexistent side effects to improve the quality of life of all cancer patients.

24 June 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Abdulaziz AlhussanAbdulaziz Alhussan
Abdulaziz Alhussan
KBKyle Bromma
Kyle Bromma
MPMonica Mesa Perez
Monica Mesa Perez
WBWayne A Beckham
Wayne A Beckham
AAAbraham Alexander
Abraham Alexander
DCDevika Chithrani
Devika Chithrani
Due to recent advances in nanotechnology, the application of nanoparticles (NPs) in cancer therapy has become a leading area in cancer research. Despite the importance of cancer-associated fibroblasts (CAFs) in creating an optimal niche for tumor cells to grow extensively, most of the work has been focused on tumor cells. Therefore, to effectively use NPs for therapeutic purposes, it is important to elucidate the extent of NP uptake and retention in tumor cells and CAFs. Three tumor cell lines and three CAF cell lines were studied using gold NPs (GNPs) as a model NP system. We found a seven-fold increase in NP uptake in CAFs compared to tumor cells. The retention percentage of NPs was three-fold higher in tumor cells as compared to CAFs. Furthermore, NP uptake and retention were significantly enhanced using a 50 nM concentration of docetaxel (DTX). NP uptake was improved by a factor of three in tumor cells and a factor of two in CAFs, while the retention of NPs was two-fold higher in tumor cells compared to CAFs, 72 h post-treatment with DTX. However, the quantity of NPs in CAFs was still three-fold higher compared to tumor cells. Our quantitative data were supported by qualitative imaging data. We believe that targeting of NPs in the presence of DTX is a very promising approach to accumulate a higher percentage of NPs and maintain a longer retention in both tumor cells and CAFs for achieving the full therapeutic potential of cancer nanotechnology.

10 October 2025 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
Abdulaziz AlhussanAbdulaziz Alhussan
Abdulaziz Alhussan
LHLouise Ho
Louise Ho
YZYao Zhang
Yao Zhang
HFHarrison Fan
Harrison Fan
AMArash Momeni
Arash Momeni
PCPieter R. Cullis
Pieter R. Cullis
Nearly half of humanity will develop cancer in their Lifetime. Current therapies, particularly chemotherapeutic drugs, face significant challenges due to the lack of tissue-specific delivery. For example, less than 0.1% of anticancer drugs administered systemically reach the tumor site, resulting in damage to healthy tissues and leading to a wide range of side effects. An effective strategy to address this problem is the encapsulation of chemotherapeutic drugs within nanoscale synthetic lipid structures, known as lipid-based nanoparticles (LBNPs). LBNPs can enhance a drug’s circulation half-life in the bloodstream and exploit the enhanced permeability and retention (EPR) effect. These delivery systems have led to the approval of more than 20 FDA-approved chemotherapeutic drugs. The greatest advantage is often improved pharmacokinetics, which enables a higher maximum tolerated dose while maintaining similar therapeutic efficacy and reducing side effects. However, a key limitation is that in many cases LBNPs are too stable, with free drug released very slowly, which limits anticancer efficacy. Consequently, externally triggered strategies have gained increasing attention, as they allow site-specific and on-demand release of LBNP contents at the tumor, thereby overcoming this stability barrier and enabling higher tumor-specific drug concentrations with fewer systemic side effects. This article reviews recent advances in externally triggered release mechanisms for LBNPs, including thermal, ultrasound, radiation, magnetic, and light-based approaches, and examines their potential integration into clinical cancer settings. Graphical Abstract

22 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Abdulaziz AlhussanAbdulaziz Alhussan
Abdulaziz Alhussan
NPNicholas Palmerley
Nicholas Palmerley
JSJulian Smazynski
Julian Smazynski
JKJoanna Karasinska
Joanna Karasinska
DRDaniel Renouf
Daniel Renouf
DCDevika Chithrani
Devika Chithrani
Many cancer therapeutics are tested in vitro using only tumour cells. However, the tumour promoting effect of cancer associated fibroblasts (CAFs) within the tumour microenvironment (TME) is thought to reduce cancer therapeutics’ efficacy. We have chosen pancreatic ductal adenocarcinoma (PDAC) as our tumor model. Our goal is to create a co-culture of CAFs and tumour cells to model the interaction between cancer and stromal cells in the TME and allow for better testing of therapeutic combinations. To test the proposed co-culture model, a gold nanoparticle (GNP) mediated-radiation response was used. Cells were grown in co-culture with different ratios of CAFs to cancer cells. MIA PaCa-2 was used as our PDAC cancer cell line. Co-cultured cells were treated with 2 Gy of radiation following GNP incubation. DNA damage and cell proliferation were examined to assess the combined effect of radiation and GNPs. Cancer cells in co-culture exhibited up to a 23% decrease in DNA double strand breaks (DSB) and up to a 35% increase in proliferation compared to monocultures. GNP/Radiotherapy (RT) induced up to a 25% increase in DNA DSBs and up to a 15% decrease in proliferation compared to RT alone in both monocultured and co-cultured cells. The observed resistance in the co-culture system may be attributed to the role of CAFs in supporting cancer cells. Moreover, we were able to reduce the activity of CAFs using GNPs during radiation treatment. Indeed, CAFs internalize a significantly higher number of GNPs, which may have led to the reduction in their activity. One reason experimental therapeutics fail in clinical trials relates to limitations in the pre-clinical models that lack a true representation of the TME. We have demonstrated a co-culture platform to test GNP/RT in a clinically relevant environment.